GeneBioTech Co. Ltd (086060) — Cash Flow-to-Debt Ratio
GeneBioTech Co. Ltd (086060) has a Cash Flow-to-Debt Ratio of -0.01x as of June 2026, meaning its operating cash flow of ₩-230.73 Million could theoretically repay 0% of its total liabilities (₩24.02 Billion) in one year. See financial agility of GeneBioTech Co. Ltd to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
GeneBioTech Co. Ltd Cash Flow-to-Debt Ratio (2009–2025)
Historical debt coverage capacity for GeneBioTech Co. Ltd across 16 annual periods. For the full cash flow conversion analysis, see 086060 cash generation efficiency.
Annual Cash Flow-to-Debt Ratio for GeneBioTech Co. Ltd (2009–2025)
Year-by-year debt coverage analysis for GeneBioTech Co. Ltd. Check GeneBioTech Co. Ltd (086060) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.37x | ₩7.61 Billion | ₩20.64 Billion | ▲ +1771.5% |
| 2024 | -0.02x | ₩-463.87 Million | ₩21.02 Billion | ▼ -105.3% |
| 2023 | 0.42x | ₩7.37 Billion | ₩17.71 Billion | ▲ +307.1% |
| 2022 | -0.20x | ₩-3.68 Billion | ₩18.31 Billion | ▼ -16.1% |
| 2021 | -0.17x | ₩-2.84 Billion | ₩16.42 Billion | ▼ -218.3% |
| 2020 | 0.15x | ₩2.49 Billion | ₩17.04 Billion | ▲ +214.5% |
| 2019 | -0.13x | ₩-2.68 Billion | ₩21.00 Billion | ▼ -152.9% |
| 2018 | 0.24x | ₩5.96 Billion | ₩24.66 Billion | ▲ +306.3% |
| 2017 | 0.06x | ₩1.13 Billion | ₩19.05 Billion | ▼ -77.5% |
| 2016 | 0.26x | ₩5.31 Billion | ₩20.14 Billion | ▲ +106.3% |
| 2015 | 0.13x | ₩2.61 Billion | ₩20.37 Billion | ▲ +42.0% |
| 2014 | 0.09x | ₩2.15 Billion | ₩23.92 Billion | ▼ -4.4% |
| 2013 | 0.09x | ₩2.38 Billion | ₩25.25 Billion | ▼ -0.2% |
| 2011 | 0.09x | ₩2.53 Billion | ₩26.79 Billion | ▼ -9.4% |
| 2010 | 0.10x | ₩1.17 Billion | ₩11.18 Billion | ▼ -56.2% |
| 2009 | 0.24x | ₩2.68 Billion | ₩11.28 Billion | — |